國立虎尾科技大學 |

Synthesis of Carboxyphosphonates and Bisphosphonates as Potential GGTase II and GGDPS Inhibitors.

紀錄類型:	書目-語言資料,手稿 : Monograph/item
正題名/作者:	Synthesis of Carboxyphosphonates and Bisphosphonates as Potential GGTase II and GGDPS Inhibitors./
作者:	Matthiesen, Robert Armin.
面頁冊數:	1 online resource (257 pages)
附註:	Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
Contained By:	Dissertation Abstracts International79-12B(E).
標題:	Organic chemistry. -
電子資源:	click for full text (PQDT)
ISBN:	9780438151444

Synthesis of Carboxyphosphonates and Bisphosphonates as Potential GGTase II and GGDPS Inhibitors.
Matthiesen, Robert Armin.

Synthesis of Carboxyphosphonates and Bisphosphonates as Potential GGTase II and GGDPS Inhibitors. - 1 online resource (257 pages)

Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.

Thesis (Ph.D.)--The University of Iowa, 2018.

Includes bibliographical references

Inhibition of enzymes in the isoprenoid biosynthetic pathway (IBP) plays an important role in the treatment of bone diseases and lowering cholesterol. The IBP begins with the enzyme HMG-CoA reductase catalyzing the conversion of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid. Mevalonic acid is then converted to isopentenyl pyrophosphate (IPP) via the intermediate mevalonate-5-diphosphate. Three molecules of IPP are joined by the enzyme farnesyl diphosphate synthase (FDPS), which yields the intermediate farnesyl pyrophosphate (FPP). FPP is an important substrate and represents the branch point in the pathway. Compounds which disrupt this pathway at FDPS include risedronate, lovastatin, and zoledronate. It is believed these compounds express their pharmacological effects on a further downstream enzyme.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2018

Mode of access: World Wide Web

ISBN: 9780438151444Subjects--Topical Terms:

1148722
Organic chemistry.
Index Terms--Genre/Form:

554714
Electronic books.

Synthesis of Carboxyphosphonates and Bisphosphonates as Potential GGTase II and GGDPS Inhibitors.
LDR:05012ntm a2200385Ki 4500 001 917825
005 20181022132248.5
006 m o u
007 cr mn||||a|a||
008 190606s2018 xx obm 000 0 eng d
020 $a 9780438151444
035 $a (MiAaPQ)AAI10680882
035 $a (MiAaPQ)uiowa:15439
035 $a AAI10680882
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Matthiesen, Robert Armin. $3 1192001
245 1 0 $a Synthesis of Carboxyphosphonates and Bisphosphonates as Potential GGTase II and GGDPS Inhibitors.
264 0 $c 2018
300 $a 1 online resource (257 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
500 $a Adviser: David F. Wiemer.
502 $a Thesis (Ph.D.)--The University of Iowa, 2018.
504 $a Includes bibliographical references
520 $a Inhibition of enzymes in the isoprenoid biosynthetic pathway (IBP) plays an important role in the treatment of bone diseases and lowering cholesterol. The IBP begins with the enzyme HMG-CoA reductase catalyzing the conversion of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid. Mevalonic acid is then converted to isopentenyl pyrophosphate (IPP) via the intermediate mevalonate-5-diphosphate. Three molecules of IPP are joined by the enzyme farnesyl diphosphate synthase (FDPS), which yields the intermediate farnesyl pyrophosphate (FPP). FPP is an important substrate and represents the branch point in the pathway. Compounds which disrupt this pathway at FDPS include risedronate, lovastatin, and zoledronate. It is believed these compounds express their pharmacological effects on a further downstream enzyme.
520 $a Further downstream from FDPS the IBP includes the key enzymes geranylgeranyl diphosphate synthase (GGDPS), which is responsible for the production of geranylgeranyl pyrophosphate (GGPP) and necessary for protein prenylation of the proteins Ras, Rho, and Rab. The second key enzyme is geranylgeranyl transferase II (GGTase II), which is responsible for the transfer of GGPP to Rab proteins. Rab proteins, which play an essential role for both protein secretion and trafficking, are of great interest as a therapeutic target for the bone disease multiple myeloma. Multiple myeloma is a disorder of malignant plasma cells, characterized by the overproduction of monoclonal protein, antibodies, or light chains, which can ultimately thicken the blood.
520 $a Targeting the prevention of geranylgeranylation of the Rab proteins by the enzyme GGTase II can happen through two different strategies. The first would be an indirect route, which would aim to inhibit the enzymes upstream from GGTase II. This could include the enzymes HMG-CoA reductase, FDPS, and GGDPS. Drugs that inhibit the earlier steps in the IBP indirectly prevent protein geranylgeranylation but they also limit formation of other key processes further downstream. The second approach would be a direct inhibition of the enzyme responsible for protein prenylation, GGTase II. There are very few know inhibitors of GGTase II. One such inhibitor is a carboxyphosphonate 3-PEHPC, a mimic of the bisphosphonate risedronate. Unfortunately, 3-PEHPC does not display an attractive potency.
520 $a Efforts to develop a more potent inhibitor of the enzyme GGTase II, have focused on the preparation of a family of carboxyphosphonates containing a triazole core, and these compounds were prepared via click chemistry. Their activity has been studied, but the salts that were successfully made were ultimately inactive in comparison to 3-PEHPC. Previous attempts at forming isoprene-containing triazole carboxyphosphonates, as isoprene chains were shown to help increase activity towards GGTase II, proved difficult and unsuccessful. Focus was then switched to alteration of isoprene bisphosphonate triazoles as GGDPS inhibitors in attempts to increase activity towards this enzyme. The biological activity of these bisphosphonates was found to be selective and potent inhibitors of GGDPS, with little to no activity towards the GGTase II enzyme.
520 $a In an effort to develop more potent inhibitors, isoprene triazole carboxyphosphonates were produced in an attempt to enhance the biological activity towards GGTase II. Along with forming a family of isoprene bisphosphonate compounds to increase the biological activity towards GGDPS in comparison to other previously made bisphosphonates. These carboxyphosphonate and bisphosphonate compounds were prepared through click chemistry and tested for their activity toward GGTase II and GGDPS.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2018
538 $a Mode of access: World Wide Web
650 4 $a Organic chemistry. $3 1148722
650 4 $a Chemistry. $3 593913
655 7 $a Electronic books. $2 local $3 554714
690 $a 0490
690 $a 0485
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a The University of Iowa. $b Chemistry. $3 1192002
773 0 $t Dissertation Abstracts International $g 79-12B(E).
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10680882 $z click for full text (PQDT)